Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study

Author:

Xu Jian Ming1,Wang Yan1,Chen Yu Ling1,Jia Ru1,Li Jie2,Gong Ji Fang2,Li Jing3,Qi Chuan3,Hua Ye3,Tan Cui Rong3,Wang Jian4,Li Ke4,Sai Yang4,Zhou Feng5,Ren Yong Xin5,Qing Wei Guo5,Jia Hong6,Su Wei Guo6,Shen Lin2

Affiliation:

1. Department of Gastrointestinal Oncology, The Affiliated Hospital Cancer Center (The 307th Hospital of Chinese People's Liberation Army), Academy of Military Medical Sciences, Beijing, China

2. Department of Gastrointestinal Oncology, Peking University Cancer Hospital, Beijing, China

3. Clinical and Regulatory Department, Hutchison MediPharma Limited, Shanghai, China

4. Drug Metabolism and Pharmacokinetic Department, Hutchison MediPharma Limited, Shanghai, China

5. Oncology Department, Hutchison MediPharma Limited, Shanghai, China

6. Chemistry Department, Hutchison MediPharma Limited, Shanghai, China

Publisher

Impact Journals, LLC

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3